Trade Lantern Pharma Inc. - LTRN CFD

Add to favourite

5.31

7.49%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.16

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Key Stats

Prev. Close*	5.74
Open*	5.49
1-Year Change*	10.02%
Day's Range*	5.18 - 5.54
52 wk Range	2.38-6.19
Average Volume (10 days)	17.31K
Average Volume (3 months)	914.80K
Market Cap	41.74M
P/E Ratio	-100.00K
Shares Outstanding	10.87M
Revenue	N/A
EPS	-1.40
Dividend (Yield %)	N/A
Beta	1.24
Next Earnings Date	Mar 18, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	5.74	-0.05	-0.86%	5.79	6.08	5.73
Apr 17, 2024	5.90	0.09	1.55%	5.81	6.13	5.58
Apr 16, 2024	5.92	0.13	2.25%	5.79	6.18	5.35
Apr 15, 2024	5.89	-0.29	-4.69%	6.18	6.45	5.79
Apr 12, 2024	6.31	-0.25	-3.81%	6.56	6.59	6.17
Apr 11, 2024	6.64	-0.64	-8.79%	7.28	7.48	6.48
Apr 10, 2024	7.63	0.04	0.53%	7.59	7.89	7.18
Apr 9, 2024	7.74	0.25	3.34%	7.49	8.16	7.48
Apr 8, 2024	7.73	0.15	1.98%	7.58	7.90	7.53
Apr 5, 2024	7.73	0.64	9.03%	7.09	8.23	7.09
Apr 4, 2024	7.16	-1.31	-15.47%	8.47	8.67	7.09
Apr 3, 2024	8.55	-0.42	-4.68%	8.97	9.20	8.37
Apr 2, 2024	9.14	0.07	0.77%	9.07	9.23	8.64
Apr 1, 2024	9.47	0.61	6.88%	8.86	9.85	8.85
Mar 28, 2024	8.72	-0.83	-8.69%	9.55	9.92	8.47
Mar 27, 2024	9.71	-0.29	-2.90%	10.00	10.07	9.01
Mar 26, 2024	9.95	-0.27	-2.64%	10.22	10.71	9.87
Mar 25, 2024	9.89	-1.08	-9.85%	10.97	11.86	9.56
Mar 22, 2024	10.58	1.57	17.43%	9.01	10.69	8.97
Mar 21, 2024	9.02	0.09	1.01%	8.93	9.72	8.92

Lantern Pharma Inc. Events

Time (UTC)	Country	Event
Tuesday, May 7, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Lantern Pharma Inc Earnings Release Q1 2024 Lantern Pharma Inc Earnings Release Forecast - Previous -
Friday, June 14, 2024
Time (UTC) 15:00	Country US	Event Lantern Pharma Inc Annual Shareholders Meeting Lantern Pharma Inc Annual Shareholders Meeting Forecast - Previous -
Wednesday, August 7, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Lantern Pharma Inc Earnings Release Q2 2024 Lantern Pharma Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	0	0	0	0	0
Total Operating Expense	14.4327	12.4825	5.90819	2.42819	1.72642
Selling/General/Admin. Expenses, Total	5.8298	5.02093	3.66497	1.475	1.15432
Research & Development	8.60295	7.57058	2.24323	0.95319	0.5721
Operating Income	-14.4327	-12.4825	-5.90819	-2.42819	-1.72642
Net Income Before Taxes	-14.2599	-12.363	-5.90819	-2.42819	-1.72642
Net Income After Taxes	-14.2599	-12.363	-5.90819	-2.42819	-1.72642
Net Income Before Extra. Items	-14.2599	-12.363	-5.90819	-2.42819	-1.72642
Net Income	-14.2599	-12.363	-5.90819	-2.42819	-1.72642
Income Available to Common Excl. Extra. Items	-14.2599	-12.363	-5.90819	-2.42819	-1.72642
Income Available to Common Incl. Extra. Items	-14.2599	-12.363	-5.90819	-2.42819	-1.72642
Diluted Net Income	-14.2599	-12.363	-5.90819	-2.42819	-1.72642
Diluted Weighted Average Shares	10.8506	10.9049	6.22093	6.03059	6.03059
Diluted EPS Excluding Extraordinary Items	-1.31421	-1.13371	-0.94973	-0.40264	-0.28628
Dividends per Share - Common Stock Primary Issue				0	0
Diluted Normalized EPS	-1.31421	-1.14371	-0.94973	-0.40264	-0.28628
Unusual Expense (Income)		-0.109
Interest Income (Expense), Net Non-Operating	0.20436	0.11948
Other, Net	-0.03155

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0	0	0	0	0
Total Operating Expense	5.1903	4.28627	3.82628	2.14526	4.39482
Selling/General/Admin. Expenses, Total	1.63208	1.73332	1.57468	1.44296	1.406
Research & Development	3.55822	2.55295	2.2516	0.7023	2.98882
Operating Income	-5.1903	-4.28627	-3.82628	-2.14526	-4.39482
Net Income Before Taxes	-4.7464	-3.86777	-3.38111	-2.26468	-4.49239
Net Income After Taxes	-4.7464	-3.86777	-3.38111	-2.26468	-4.49239
Net Income Before Extra. Items	-4.7464	-3.86777	-3.38111	-2.26468	-4.49239
Net Income	-4.7464	-3.86777	-3.38111	-2.26468	-4.49239
Income Available to Common Excl. Extra. Items	-4.7464	-3.86777	-3.38111	-2.26468	-4.49239
Income Available to Common Incl. Extra. Items	-4.7464	-3.86777	-3.38111	-2.26468	-4.49239
Diluted Net Income	-4.7464	-3.86777	-3.38111	-2.26468	-4.49239
Diluted Weighted Average Shares	10.857	10.857	10.8571	10.8389	10.8309
Diluted EPS Excluding Extraordinary Items	-0.43717	-0.35624	-0.31142	-0.20894	-0.41477
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.43717	-0.35624	-0.31142	-0.20894	-0.41477
Unusual Expense (Income)
Interest Income (Expense), Net Non-Operating	0.11782	0.13378	0.07468	0.05222	0.05503
Other, Net	0.32608	0.28472	0.37049	-0.17165	-0.15259

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	58.7227	72.7164	20.2369	1.23282	0.44516
Cash and Short Term Investments	55.1961	70.7254	19.2292	1.23203	0.44516
Cash	37.2018	51.5243	19.2292	1.23203	0.44516
Total Assets	58.8363	73.9505	20.3596	1.43258	0.44983
Property/Plant/Equipment, Total - Net	0.0957	0.21619	0.02151	0.00876	0.00467
Other Long Term Assets, Total	0.01789	1.01789	0.10121	0.191	0
Total Current Liabilities	2.7983	2.32617	0.55234	0.48929	0.65163
Payable/Accrued	2.74541	2.17411	0.55234	0.48929	0.11663
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total					0.535
Total Liabilities	2.7983	2.37906	0.66084	0.48929	0.65163
Total Long Term Debt	0	0	0.1085	0	0
Total Equity	56.038	71.5714	19.6988	0.94328	-0.2018
Redeemable Preferred Stock				0.01402	0.00743
Common Stock	0.00109	0.00111	0.00062	0.01137	0.01137
Additional Paid-In Capital	95.6912	96.6859	32.3581	7.6696	4.10292
Retained Earnings (Accumulated Deficit)	-39.2829	-25.0229	-12.6599	-6.75171	-4.32352
Total Liabilities & Shareholders’ Equity	58.8363	73.9505	20.3596	1.43258	0.44983
Total Common Shares Outstanding	10.857	11.0888	6.22093	6.03059	6.03059
Prepaid Expenses	2.98547	1.99095	1.00769	0.00079
Long Term Debt		0	0.1085
Short Term Investments	17.9943	19.2012
Accrued Expenses	0.05289	0.15206
Other Liabilities, Total	0	0.05289
Other Equity, Total	-0.37139	-0.09269
Other Current Assets, Total	0.54118

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	47.426	51.042	55.1676	58.7227	62.0198
Cash and Short Term Investments	44.9256	47.949	51.5401	55.1961	57.8266
Cash	25.5717	28.4232	32.4788	37.2018	39.2579
Prepaid Expenses	2.5004	2.5518	3.08633	2.98547	3.65197
Total Assets	47.7715	51.426	55.5093	58.8363	62.1644
Property/Plant/Equipment, Total - Net	0.31966	0.35821	0.30879	0.0957	0.12673
Other Long Term Assets, Total	0.02587	0.02587	0.03297	0.01789	0.01789
Total Current Liabilities	2.25331	3.01598	2.79319	2.7983	3.139
Payable/Accrued	2.0853	2.85284	2.6736	2.74541	3.04697
Notes Payable/Short Term Debt	0	0	0	0	0
Total Liabilities	2.35983	3.16669	2.93382	2.7983	3.139
Total Long Term Debt	0	0	0	0	0
Long Term Debt
Total Equity	45.4117	48.2593	52.5755	56.038	59.0254
Common Stock	0.00109	0.00109	0.00109	0.00109	0.00109
Additional Paid-In Capital	96.6079	96.4171	96.0247	95.6912	95.3611
Retained Earnings (Accumulated Deficit)	-51.0585	-47.897	-43.1506	-39.2829	-35.9018
Total Liabilities & Shareholders’ Equity	47.7715	51.426	55.5093	58.8363	62.1644
Total Common Shares Outstanding	10.869	10.869	10.857	10.857	10.857
Short Term Investments	19.3538	19.5258	19.0613	17.9943	18.5687
Accrued Expenses	0.16801	0.16315	0.11958	0.05289	0.09202
Other Current Liabilities, Total
Other Liabilities, Total	0.10652	0.15071	0.14063	0	0
Other Equity, Total	-0.13879	-0.26184	-0.29968	-0.37139	-0.43504
Other Current Assets, Total	0	0.54118	0.54118	0.54118	0.54118

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-14.2599	-12.363	-5.90819	-2.42819	-1.72642
Cash From Operating Activities	-12.7675	-10.5915	-5.65162	-2.12792	-1.27152
Non-Cash Items	2.09424	1.16477	1.19224	0.11776	0.18306
Changes in Working Capital	-0.61186	0.59996	-0.93906	0.18088	0.27184
Cash From Investing Activities	0.17927	-19.5306	-0.01614	-0.00572	0.00534
Other Investing Cash Flow Items, Total	0.20711	-19.5151			0.00534
Cash From Financing Activities	-2.1825	63.4161	23.665	2.92051	0.535
Financing Cash Flow Items	0	-4.78382	-2.74554	0	0.535
Issuance (Retirement) of Stock, Net	-2.1825	68.1999	26.302	2.92051	0
Net Change in Cash	-14.7813	33.2951	17.9972	0.78687	-0.73118
Cash From Operating Activities	0.01008	0.00676	0.00339	0.00163
Capital Expenditures	-0.02784	-0.0155	-0.01614	-0.00572
Issuance (Retirement) of Debt, Net		0	0.1085
Foreign Exchange Effects	-0.01061	0.00107

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-3.86777	-14.2599	-10.8788	-8.61416	-4.12177
Cash From Operating Activities	-3.75716	-12.7675	-10.0986	-6.06036	-3.32773
Cash From Operating Activities	0.00342	0.01008	0.00732	0.00437	0.00199
Non-Cash Items	0.34754	2.09424	1.76509	1.16612	0.5284
Changes in Working Capital	-0.24035	-0.61186	-0.9922	1.3833	0.26366
Cash From Financing Activities	0	-2.1825	-2.1825	-2.1825	-2.1825
Financing Cash Flow Items		0	0	0	0
Issuance (Retirement) of Stock, Net	0	-2.1825	-2.1825	-2.1825	-2.1825
Issuance (Retirement) of Debt, Net
Net Change in Cash	-4.72302	-14.7813	-12.7252	-8.62025	-5.33143
Cash From Investing Activities	-0.96088	0.17927	-0.42359	-0.34923	0.17652
Capital Expenditures	-0.00888	-0.02784	-0.02089	-0.01418
Other Investing Cash Flow Items, Total	-0.952	0.20711	-0.4027	-0.33505	0.17652
Foreign Exchange Effects	-0.00498	-0.01061	-0.02051	-0.02816	0.00228

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Lantern Pharma Inc. Company profile

About Lantern Pharma Inc.

Lantern Pharma Inc. is a clinical stage biopharmaceutical company. The Company is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Lantern Pharma Inc. revenues was not reported. Net loss increased from $5.9M to $12.4M. Higher net loss reflects Research and development increase from $2.2M to $7.6M (expense), General and administrative - Balancing v increase of 99% to $4.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.95 to -$1.13.

Industry:

Biotechnology & Medical Research (NEC)

1920 Mckinney Avenue
7th Floor
DALLAS
TEXAS 75201
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024